Recently, the interest in therapeutic applications of peptides has grown tremendously due to their unique characteristics. Since 2016, at least 26 therapeutic peptides have been approved for clinical use by FDA, and several peptide candidates are currently in clinical trials. Specifically, the approval of oral semaglutide (Rybelsus®) in 2019 for treating type 2 diabetes marked a significant milestone in the advancement of peptide therapeutics.